Building Strength at the Given Site
The Association of Research-Based Pharmaceutical Manufacturers recently held a discussion titled "Strong at the Location - Live" before the federal election, focusing on the role of the next government in shaping Germany's economic and innovation landscape, the healthcare system, and the future of the pharmaceutical industry in Germany.
The event emphasized the importance of a stable and innovation-friendly policy framework by the incoming government to sustain and strengthen Germany as a leading location for pharmaceutical research and manufacturing. Calls were made for clear, long-term political commitments to support innovation and investment.
Discussions highlighted Germany’s current strengths as a hub for pharmaceutical research and development, including its world-class infrastructure, skilled workforce, and well-established networks between academia and industry. However, challenges such as regulatory hurdles and competition from other countries were also addressed.
The event covered the need to balance cost efficiency with innovation in the healthcare system, ensuring patients have timely access to cutting-edge therapies. Participants called for reforms that streamline market access for new medicines while maintaining a sustainable healthcare budget.
The future outlook included the necessity for ongoing investment in research and development, digitalization, and sustainability. The industry advocated for policies that encourage innovation, support supply chain resilience, and foster collaboration between public and private sectors to secure Germany’s position as a global pharmaceutical hub.
The discussion featured guests from both politics and the pharmaceutical industry, addressing how the resilience and innovation of the healthcare system could look in the future, as well as the tasks of the next government and new impulses for the economic and innovative location Germany.
However, it's important to note that the discussion did not provide specific details about the exact timeline for the implementation of the discussed topics, the resilient, innovative healthcare system, the new impulses for the economic and innovative location Germany, or the tasks of the next government. These aspects were discussed in the context of the future.
In conclusion, the event underscored collaborative efforts between policymakers, industry, and healthcare stakeholders to create a competitive, innovative, and patient-centric pharmaceutical environment in Germany post-election.
The Association's discussion stressed the need for a supportive financial climate, as business investments and scientific advancement in the pharmaceutical sector rely on it.
Health-and-wellness reforms were advocated for, requiring a focus on medical-conditions and technological innovation, ensuring affordable access to quality healthcare for the German public.
Long-term assurance of funding for research in health and finance, digitalization, and sustainability was deemed essential for Germany to remain a competitive global hub for pharmaceutical science and business.
